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Introduction

T

he use of laboratory animals in (biomedical) research
keeps provoking moral debates in society, which tend
to revolve around two fundamental questions: (1) Are
animal experiments morally acceptable? And (2) for which
experiments are the expected beneﬁts to humans (or to other
animals or the environment) sufﬁcient to outweigh the suffering of the laboratory animals? A third, and often absent, moral
question is: How should the experiments that are justiﬁed be
designed, conducted, and analyzed? Initially, this question
appears to be scientiﬁc rather than moral, but if animal
experiments are not appropriately designed, conducted, and
analyzed, the results produced are likely to be unreliable. If
the results of the experiments cannot be trusted, the animals
used have in effect been wasted (Ioannidis et al. 2014).
Such use and suffering of animals not counterbalanced by
beneﬁt in terms of science and/or human health is morally
unjustiﬁable.
The aim of this article is to discuss the use of systematic
review (SR) to address this third moral question. We will
illustrate how the design, conduct, and analysis of future
(animal and human) experiments may be optimized through
systematic reviews of previously performed experiments.
A systematic review is a literature review to address a speciﬁc research question by seeking to identify, select, appraise,
and synthesize all available research evidence relevant to that
question (Egger et al. 2001). Systematic reviews follow a
series of standard steps (see Box 1). This structured process
highlights the differences between systematic reviews
and classical, narrative reviews (for a summary of these differences, see Table 1). An SR often starts by formulating the
research question that the review will try to answer. This
research question tends to have a narrow focus (e.g., what is
the effect of omega-3 fatty acids on Aβ deposition and cognition in animal models for Alzheimer’s disease?). Authors of
narrative reviews generally aim to provide an expert opinion
on a certain research topic or give an overview of recent
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The question of how animal studies should be designed,
conducted, and analyzed remains underexposed in societal
debates on animal experimentation. This is not only a scientiﬁc but also a moral question. After all, if animal experiments
are not appropriately designed, conducted, and analyzed, the
results produced are unlikely to be reliable and the animals
have in effect been wasted. In this article, we focus on one
particular method to address this moral question, namely systematic reviews of previously performed animal experiments.
We discuss how the design, conduct, and analysis of future
(animal and human) experiments may be optimized through
such systematic reviews. In particular, we illustrate how these
reviews can help improve the methodological quality of animal experiments, make the choice of an animal model and the
translation of animal data to the clinic more evidence-based,
and implement the 3Rs. Moreover, we discuss which measures are being taken and which need to be taken in the future
to ensure that systematic reviews will actually contribute to
optimizing experimental design and thereby to meeting a
necessary condition for making the use of animals in these
experiments justiﬁed.

Key Words: experimental design; systematic review; metaanalysis; animal model; animal ethics; 3Rs; evidence-based
preclinical medicine; translation

Box 1 Steps of a systematic review
1.
2.
3.
4.
5.
6.
7.
8.
9.

Formulating a focused research question
Preparing a protocol
Deﬁning inclusion and exclusion criteria
Systematically searching for original papers in at least
two databases
Selecting the relevant papers
Assessing the quality/validity of the included studies
Extracting data
Data synthesis (if feasible, meta-analysis)
Interpreting the results

Feature

Narrative
review

Research
question

Often unclear
or broad

Specified and specific

Literature
sources and
search

Not usually
specified

Comprehensive
sources (more than
one database) and
explicit search
strategy

Study selection

Not usually
specified

Explicit selection
criteria and selection
by two independent
reviewers

Quality
assessment
included
studies

Not usually
present or
only implicit

Critical appraisal on the
basis of explicit
quality criteria

Synthesis

Often a
qualitative
summary

Often also a
quantitative summary
(meta-analysis)

Systematic review

developments in a particular ﬁeld. The inclusion of studies in
the review is therefore often based on the authors’ expert
knowledge of the research ﬁeld. This approach could introduce a risk of subjectivity in the selection of relevant studies.
In order to reduce the risk of subjectivity, authors of SRs are
encouraged to prespecify the different steps of the review in a
protocol. As part of the protocol, the criteria for selecting
studies are determined a priori. Thus, studies cannot be included or excluded based on the direction of their ﬁndings.
Because SRs aim to include all evidence relevant to the research question, they generally use comprehensive search
strategies. To prevent missing relevant studies, authors of
428

Advantages of Systematic Reviews
for Designing Experiments
In order to draw reliable conclusions regarding the causal
relationship between the intervention studied and the effects
observed, it is vital that experiments are designed appropriately. Experimental design choices may include, but are not
limited to, the choice of experimental and control groups,
the determination of sample size, the choice of animal or
disease model, and the measures taken to reduce the introduction of bias (Festing et al. 2002). In general, SRs of animal
studies can guide the design of new experiments by demonstrating the extent of current evidence in the ﬁeld and providing insight into which questions need to be addressed. In
addition, SRs of animal studies can contribute to (1) improving the methodological quality of experiments, (2) an
ILAR Journal
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Table 1 Differences between systematic and
narrative reviews

SRs are advised to search in at least two databases, for example, PubMed and Embase. Moreover, the search strategy is
described in detail, enabling other researchers to replicate
the search and to assess its completeness (Leenaars et al.
2012a). From the set of studies identiﬁed through the comprehensive search strategy, two independent reviewers select the
papers to be included in the review on the basis of the
previously deﬁned inclusion and exclusion criteria.
After study selection has been completed, in most SRs, the
methodological quality of the included studies is critically
appraised (Henderson et al. 2013; van Luijk et al. 2014).
This may include an assessment of their risk of bias, usually
performed by two independent reviewers (Hooijmans et al.
2014; Krauth et al. 2013). Such an explicit and structured
assessment of the reliability of studies included in a review
is uncommon in narrative reviews. In addition to the quality
assessment, the characteristics of the individual studies
(design, species, intervention, outcome measures, etc.) are
extracted. Where included studies contain quantitative outcome data and have sufﬁciently similar characteristics, these
data may be statistically pooled using meta-analysis. Such an
analysis produces a more precise estimate of the effect of an
intervention. For a detailed explanation of the concept of
meta-analysis and the added value of including such an analysis in an SR of animal studies, see the article by Hooijmans
et al. elsewhere in this special issue.
SRs are common practice in clinical research, particularly
for randomized controlled trials. Despite the fact that most
animal experiments are performed to inform clinical research,
SRs of animal experiments are still rather scarce (Korevaar
et al. 2011; Peters et al. 2006; van Luijk et al. 2014). This is
unfortunate, because SRs have several scientiﬁc advantages
from the perspective of both human health and the 3Rs
(Hooijmans and Ritskes-Hoitinga 2013; Sena et al. 2014).
Here we will illustrate these advantages by showing in which
ways SRs may help improve the design of new animal and
clinical studies. In the ﬁnal section, we will discuss measures
to promote the implementation of SRs and thereby enhance
their contribution to evidence-based preclinical science.

evidence-based choice of animal model, (3) evidence-based
translation of animal data to the clinic, and (4) implementing
the 3Rs.

Improving the Methodological Quality
of Experiments

Volume 55, Number 3, doi: 10.1093/ilar/ilu043
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More Evidence-Based Selection
of Animal Models
Another crucial aspect of the design of experiments is the
choice of animal model. In this context, the term “animal
model” does not only refer to the species or strain of laboratory animal, but also to the way in which a disease or defect is
induced. Several studies have shown that the selection of
animal models for experiments is not always evidence-based
(de Vries et al. 2012; van der Worp et al. 2010a). Firstly, practical reasons—for example, costs of buying and housing the
animals, ease of handling, and availability of biochemical
429
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The term “methodological quality” can refer to the risk of
bias in a study as well as to other methodological criteria
such as imprecision or lack of power (Krauth et al. 2013).
Risk of bias is the risk of systematic errors in the determination of the magnitude or direction of the results (Higgins and
Green 2008). In this section, we will focus on risks of bias
related to the internal validity of studies and how SRs can
contribute to reducing those risks. Our general line of argumentation, however, also applies to other aspects of bias
and methodological quality.
The credibility of the inferred causal relationship between
an intervention and outcome is, in part, dependent upon the
internal validity of the experiment. An experiment is internally valid if the differences in results observed between the
experimental groups can, apart from random error, be attributed to the intervention under investigation. This validity is
threatened by certain types of bias, where systematic differences between experimental groups other than the intervention of interest are introduced, either intentionally or
unintentionally. Where such systematic differences occur, it
is no longer clear whether differences in results between
experimental groups are caused by the intervention under
investigation. Such biases may be introduced at different stages of an experiment: they may be present in the baseline characteristics of the experimental groups (selection bias), in the
care for the animals or the administration of the intervention
( performance bias), in the way the outcomes are assessed
(detection bias), and in the way dropouts are handled (attrition
bias). These threats to internal validity can be greatly reduced
by a combination of randomization and blinding on three
levels: (1) the allocation of animals to experimental groups,
(2) the administration of care and interventions during the experiment, and (3) the assessment of outcome (Hooijmans
et al. 2014). Several studies have demonstrated that investigators rarely report measures to ensure the internal validity of
experiments, such as randomization and blinding (Kilkenny
et al. 2009; Mignini and Khan 2006; van Luijk et al. 2014).
SRs of animal studies may be used to demonstrate the
importance of maximizing the internal validity of animal
experiments to researchers and other stakeholders (e.g., policy makers and funding agencies). Quality assessments in SRs
often contain several items related to internal validity (van
Luijk et al. 2014). The results of such an assessment give
insight into the extent to which the conclusions of the SR
may be affected by biases related to internal validity. These
results can be depicted per primary study, showing the lack
of measures to reduce bias in a particular study, or per risk
of bias item, showing the general score of the included studies
for particular biases (for examples, see Table 2 and Figure 1).

A factor currently hampering the assessment of the internal
validity is the poor reporting quality of many animal studies.
Because many details of the design and conduct of animal
experiments are not reported, it is often unclear whether measures to preserve internal validity are not applied or whether
they are applied but their application is not reported. In order
to assess the actual risk of bias, the reporting quality of animal
studies needs to improve (Hooijmans et al. 2014).
Moreover, SRs of animal studies can provide further
empirical evidence that a lack of measures to reduce bias
can lead to an overestimation or underestimation of the true
effect of an intervention (Crossley et al. 2008). The results
of the assessment of internal validity per study can be used
in meta-analysis to compare subgroups of studies that, for
example, did and did not report randomization of the allocation of animals to the experimental groups. Using this
approach, an SR of therapeutic hypothermia in experimental
models of stroke found that observed treatment effects were
10% larger in studies that did not report randomization and
8% larger in studies that did not report blinding than in those
that did take these measures to reduce bias (van der Worp
et al. 2007). Similarly, an SR of the drug NXY-059 in experimental stroke showed that the estimate of effect of NXY-059
was reported to be 30% larger in studies that did not report
randomization or blinding than in studies that did (Figure 2)
(Macleod et al. 2008). It is important to stress that this relationship between these measures to reduce bias and overestimation of effects has not been observed in all cases. In an SR
of temozolomide in models of glioma, for instance, greater
reductions in tumor volume were observed in blinded studies
as compared to studies that did not report blinding (Hirst et al.
2013). However, this ﬁnding may be due to the fact that very
few studies reported blinding (n = 2 vs. blinding not reported:
n = 24), reducing the power of such an analysis. This highlights the limitations of this approach, which should be considered to be hypothesis generating rather than conﬁrmatory.
SRs of clinical trials provided evidence of the number of
studies that did not randomize or blind and of the impact of
the lack of these measures to reduce bias on outcome. This
raised awareness of the importance of preserving internal
validity and thereby helped improve the design and reporting
of new studies (Mullen and Ramirez 2006). We hope for similar
improvements in the conduct and reporting of animal studies.
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Table 2 Example of risk of bias assessment of individual studies (from Hooijmans et al. 2012)
Question
Nr.

Akyol,
2003

Chen,
2007

Deng,
2000

Horst,
2009

Karen,
2010

Lutgendorff,
2008

Mangiante,
2001

Muftuoglu,
2006

Qin,
2006

Sahin,
2007

Tarasenko,
2000

v Minnen,
2006

Yang,
2006

1

yes

yes

yes

yes

yes

yes

no

yes

yes

no

no

yes

yes

2

?

?

?

?

?

?

?

?

yes

?

2

?

?

?

3

?

?

?

?

?

?

na

?

?

na

na

?

?

4

?

?

?

?

?

yes

?

?

?

?

?

yes

?

5

yes*

?

?

yes*

yes*

yes

yes

yes*

?

?

?

yes

?

6

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

7

?

?

?

?

?

yes

no

no

?

?

no

yes

no

8

?

?

?

?

?

?

?

?

?

?

?

?

?

9

yes

yes

yes

yes

yes

yes

yes #

yes

yes

yes

?

yes

?

10

no

na

na

yes

yes ^^

na

na

na

na

na

no

yes

yes

yes = low risk of bias; no = high risk of bias; ? = unclear risk of bias; Abbreviation: na = not applicable. * = assessment of the outcome measure histopathology was blinded, other relevant outcome
measures were not blinded.
^ ^Risk of bias in the analysis because animals were replaced. # solely animals with severe acute pancreatitis are included in the analysis (risk of underestimating the effect of probiotics).
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Figure 2 Subgroup analysis based on study quality (from Macleod et al. 2008). Grey horizontal bar depicts 95% conﬁdence interval of overall
effect estimate.

tests—tend to play as important a role in the selection of the
animal model as the (anticipated) translational value. Secondly, the selection is often not the result of an explicit and extensive comparison between different potentially suitable
models. A qualitative interview with researchers in the ﬁeld
of cartilage tissue engineering showed that some of them
were only familiar with the characteristics of the model
they themselves used and had very limited knowledge about
alternative models (de Vries et al. 2012).
SRs support an evidence-based choice of animal models
by providing a comprehensive overview of the models used
so far, including their respective advantages and disadvantages.
Thus, they provide evidence as to which model is likely to be
most suitable for a new animal experiment. Alternatively, they
might show that none of the available models is adequate and
that new models need to be developed.
SRs may explicitly aim to provide the basis for selecting
animal models (Ahern et al. 2009; Roosen et al. 2012). In
addition, they may produce such evidence as a byproduct
of answering another research question. In an SR of adaptive
changes of mesenteric arteries in pregnancy, for instance, van
Drongelen and colleagues (van Drongelen et al. 2012) found
that the pathways involved in the response of mesenteric
arteries to pregnancy vary considerably between different
Volume 55, Number 3, doi: 10.1093/ilar/ilu043
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strains of rats (Table 3). Moreover, the response in Wistar
rats appears to model the response seen during normal
pregnancy in healthy women, whereas the response in
Sprague-Dawley rats appears to model the response of
women showing vascular maladaptation, such as preeclampsia. This ﬁnding underlines that researchers designing new
animal experiments must be clear about which aspects of a
condition they want to study and must be careful in
selecting a species or strain of laboratory animal (van der
Graaf et al. 2013).

Evidence-Based Translation
The majority of animal experiments are carried out to gather
information about human health and disease. In preclinical
research, animal experiments explicitly aim to investigate
the safety and/or efﬁcacy of interventions intended for use
in humans. Moreover, the contribution animal experiments
may make to developing new treatments for human diseases
is an important reason for their moral justiﬁcation.
It is becoming increasingly clear, however, that it is not
straightforward to translate results found in laboratory
animals to patients in clinical trials. In many cases, the
431
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Figure 1 Risk of bias per item (from Hooijmans et al. 2012). Percentages at top refer to percentages of included studies with a particular risk of
bias score. Yes = low risk of bias; no = high risk of bias; unclear = unclear risk of bias; na = not applicable.

Table 3 Summary of qualitative changes in
mesenteric artery adaptation to pregnancy (from:
van Drongelen et al. 2012)
Early
Late
gestation Midgestation gestation
WR SDR WR

SDR

WR SDR

Vasodilator
- GqEC

.

.

.
↑

=2

1

.

=4

↑3

↑

1

↑1

.

.

- Vascular
compliance

.

↑1

=1

↑1

=1

↑2

- GsSMC

.

.

↑1

.

↓1

↑4

.

.

=1

=4

=6

↓ 12

1

1

2

?3

Vasoconstrictor
- GqSMC
- Myogenic reactivity

.

=

1

=

=

=

Pregnancy-induced vascular function: increase (↑), decrease (↓), no
change ( = ), inconsistent effects (?), no effects reported (.). Superscripted values represent number of responses on which the effect
is based.
Abbreviations: WR, Wistar rat; SDR, Sprague-Dawley Rat; Gq/Gs,
G-protein coupled receptor pathway; EC, endothelial cell; SMC,
smooth muscle cell.

predictive value of animal experiments is low (McGonigle
and Ruggeri 2014). One of the most dramatic examples is
stroke research. Over the past three decades, over a thousand
interventions for stroke have been tested for safety and efﬁcacy in animal experiments. More than 500 of these interventions showed evidence of efﬁcacy in animal tests, but so far
only thrombolysis with tissue plasminogen activator (tPA)
has proved to be effective in stroke patients (O’Collins
et al. 2006).
It is plausible that the striking differences in results
between animal and human studies are partly due to fundamental biological/physiological differences between humans
and other species. However, other, avoidable factors related to
the design, conduct, and reporting of preclinical animal
experiments may play an equally important role, notably
(1) poor methodological quality, (2) differences in design
between experimental animal studies and clinical trials, and
(3) publication bias. Avoiding these factors may improve the
internal and external validity and thereby the predictive value
of animal experiments (Hooijmans and Ritskes-Hoitinga 2013;
Sena et al. 2014; van der Worp et al. 2010a).
SRs are useful to identify these design-related factors in the
short run and to promote their avoidance in the long run. In
2008, the results were published of a clinical trial that was
testing probiotics as an alternative to antibiotics for the
treatment of acute pancreatitis (Besselink et al. 2008). No
differences between experimental groups were found for
432
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- Flow-mediated
vasodilation

any of the primary endpoints. Moreover, mortality in the probiotics group was signiﬁcantly higher than in the placebo
group. This outcome was unexpected in light of the results
of the animal studies preceding the start of the trial. However,
an SR of the animal data by Hooijmans and colleagues (2012)
revealed that, prior to the start of the clinical trial, no animal
experiment with a design similar to the trial had been carried
out. None of the animal experiments used the same probiotics
as were used in the trial (Ecologic 641), the probiotics
were often administered before the induction of pancreatitis
( prophylactically rather than therapeutically), and none of
the animal studies used an intrajejunal administration route,
as was used in the clinical trial (Hooijmans et al. 2012).
Similar discrepancies were found in an animal SR of the
antioxidant tirilazad (Sena et al. 2007), which appeared to
be effective in animal models of acute ischemic stroke, but
which increased the risk of death and dependency in patients.
Sena and colleagues found that time to treatment was substantially longer in the clinical studies (median 5 h) than in the
animal studies (median 10 min). Moreover, only a small number of studies used comorbid animals, whereas many comorbidities such as hypertension, diabetes, or hyperlipidemia are
common in stroke patients.
Further, the conduct of an SR of animal studies before the
start of a clinical trial can help establish whether there is
sufﬁcient evidence of sufﬁcient quality to justify the trial
and can inform the design of the trial. An example is the
SR by Wever and colleagues of ischemic preconditioning
(IPC) as a therapy against renal damage (Wever et al.
2012). IPC is a strategy in which brief periods of ischemia
and reperfusion are used to induce protection against subsequent ischemia-reperfusion injury, for example, after kidney
transplantation or cardiovascular surgery. Wever and colleagues showed that IPC protocols studied in animal models
were diverse in terms of timing, duration, and the number of
ischemic and reperfusion periods used. In the animal studies,
IPC protocols applied 24 hours or more in advance of the prolonged ischemic insult reduced renal injury more effectively
than protocols performed within 24 hours of the index
ischemia. Interestingly, remote IPC (where the brief ischemic
stimuli are not applied to the kidney itself, but to another
organ or tissue) was not studied extensively in animals,
even though it is the preferred method of IPC in human
patients. Meta-analysis suggested that these two types of
IPC might be equally effective in animal models of renal
reperfusion injury. Up to 2012, all clinical trials applied nearly identical IPC protocols: three or four cycles of ﬁve minutes
ischemia and reperfusion, applied directly before the index
ischemia.
Thus, in light of the animal data, clinical trials of therapeutic IPC for renal injury may have been suboptimally designed.
Based on the results of their animal SR, Wever and colleagues
designed a clinical trial in which IPC will be applied either
directly before renal damage, 24 hours in advance, or both.
Furthermore, since the publication of this SR, several clinical
trials have been registered on Clinicaltrials.gov that apply IPC
24 hours or more before ischemic injury (e.g., trial numbers

Implementation of the 3Rs
Apart from their potential use in designing new animal (and
human) studies, SRs may also contribute to the development
of alternatives to animal experiments. The term “alternatives”
is taken here to refer to the 3Rs of replacement, reduction, and
reﬁnement (Russell and Burch 1959).
Replacement
SRs alone will rarely replace animals or animal experiments
directly, although they can prevent unnecessary duplication
of experiments or show that proposed experiments do not
add substantially to current knowledge. However, they can
contribute indirectly to replacement by supporting the development or validation of replacement alternatives. For
instance, an SR of replacement alternatives based on tissue
engineering (de Vries et al. 2013) demonstrated that the
potential for the development of these alternatives is broader
than use of tissue-engineered skin for toxicological applicaVolume 55, Number 3, doi: 10.1093/ilar/ilu043
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tions. Previous, narrative reviews had either discussed only a
few examples or addressed only one area of application, for
example, safety testing. By providing a comprehensive
overview, the SR helped to make both tissue engineers and
alternative experts aware of the full range of possibilities
of using tissue-engineered constructs as a replacement of
laboratory animals.
Additionally, SRs of animal studies can be incorporated
into assessments of how well alternative test methods perform
in comparison to the animal-based methods they are intended
to replace. Such comparative reviews could be loosely
likened to retrospective validation (Hartung 2010). The
Evidence-based Toxicology Collaboration (EBTC; www.
ebtox.com) is pioneering this application of SRs in an assessment of the performance of the Zebraﬁsh Embryo Test (ZET)
in predicting the results of prenatal developmental toxicity
tests (see Test Guideline 414 of the Organisation for Economic Co-operation and Development [2001]). The goal of
such developmental toxicity tests is to assess the effects of
chemical exposure on the growth and development of the
fetus. The current mammalian-based tests have signiﬁcant
limitations; they are animal use-intensive, costly, and timeconsuming (Selderslaghs et al. 2012).
The goals of the EBTC’s SR are to assess the ZET’s performance compared to that of the established mammalian
tests and, more broadly, to serve as a methodological case
study to assess the feasibility of using an SR-based approach
for the evaluation of (alternative) test methods. The ZET is
currently considered a screening tool for prenatal developmental toxicity (Adler et al. 2011; Basketter et al. 2012).
A good test performance would underscore the ZET’s use
as a screening tool and possibly provide evidence to extend
its use as a partial substitute for mammalian testing. The
EBTC also plans to assess in a similar way the performance
of the high-throughput cellular and biochemical assays at
the heart of “21st century toxicology” (Stephens et al.
2013). Such assays typically do not correspond, one to
one, to existing methods, making their validation especially
challenging.

Reduction and Refinement
SRs contribute to reduction by making further use of the data
already available, thereby producing new scientiﬁc information without the use of new animals. Moreover, SRs may
improve the design and therefore the relevance and reliability
of new experiments, leading to more reliable information
from the same number of animals.
It is still unclear, however, whether the large-scale application of SRs of animal studies will reduce the absolute number
of animals used. An SR of animal models of multiple sclerosis (Vesterinen et al. 2010) showed that many animal experiments in the ﬁeld are underpowered and that adequately
powered experiments would have required more, rather than
fewer, animals. However, such adequately powered experiments would produce more reliable data that would require
433
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NCT01903161, NCT01658306, and NCT01739088). Similarly, an SR of therapeutic hypothermia for animal models
of ischemic stroke was used to inform the design of the
EuroHYP-1 clinical trial (van der Worp et al. 2010b; van
der Worp et al. 2007).
Unfortunately, the use of SRs of animal studies to help
improve the translational value of animal experiments is likely to be further hampered by the presence of publication
bias. Publication bias is bias caused by the phenomenon
that studies reporting statistically signiﬁcant data are much
more likely to get published than studies reporting neutral
or negative data (Higgins and Green 2008; Song et al.
2010). There are strong indications that publication bias is far
more abundant in the ﬁeld of animal studies than in clinical research (Korevaar et al. 2011; ter Riet et al. 2012). Meta-analyses
have suggested that publication bias may lead to major overstatements of treatment effects (Sena et al. 2010b). Funnel
plot inspection, Egger regression, and trim-and-ﬁll analysis
are common tools in SRs to assess the likelihood of publication
bias and its impact on the conclusions drawn (see also the article
by Hooijmans et al. in this special issue).
An essential role in the long-term solution to minimizing
publication bias may be played by registries, similar to the
ones established in the ﬁeld of clinical research (for example,
ClinicalTrials.gov) (Dickersin 1990). However, there are likely to be more impediments to establishing such registries in
the preclinical ﬁeld. Major objections to the registration of
preclinical studies are that such registries might (1) threaten
the strategic advantage ( private) drug developers have over
their competitors; (2) create an undue administrative burden
for researchers, especially in basic science; and (3) prove
too costly (Kimmelman and Anderson 2012). These objections can largely be met, however, by appropriately streamlining the content of such registries and limiting access to
sensitive information.
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Figure 3 Cumulative meta-analysis of the effect of tPA on stroke (each time a new animal study is published, the overall effect size is recalculated for all studies available at that time, resulting in an increasingly more precise estimate of the effect of the intervention) (from Sena et al.
2010a). Values expressed as effect size + 95% conﬁdence intervals.

larger but probably fewer experiments and that would at least
prevent waste of animals.
On a smaller scale, SRs can reduce the number of animals
by preventing the conduct of experiments not necessary to
establish a certain effect of an intervention. Cumulative metaanalysis has great potential for this purpose. In a cumulative
meta-analysis, studies are sequentially included in the metaanalysis, and the point at which sufﬁcient data exist to show
stability of a treatment effect can be observed. This technique
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has been used in clinical studies to identify at which point
there are sufﬁcient data to refute or support drug efﬁcacy
and whether further trials are required (Lau et al. 1992). An
SR of tPA in models of stroke (Sena et al. 2010a) showed that
a total of 3,388 animals had been used. A cumulative metaanalysis included in this SR suggested that the estimate of
efﬁcacy was stable from around the inclusion of 1500 animals
(see Figure 3). It is important to note that many of the experiments in this SR were using tPA as a positive control (as the
ILAR Journal

Progress in Implementing Systematic
Reviews
From a scientiﬁc and moral perspective, animal experiments
should be appropriately designed, correctly performed, thoroughly analyzed, and transparently reported. In this ﬁnal
section, we want to highlight a number of recent and future
initiatives/activities that have been, are, or will be undertaken
in order to ensure that SRs of animal studies are conducted
and thereby actually contribute to achieving that ideal situation (Hooijmans and Ritskes-Hoitinga 2013).
Two major research groups involved in the promotion of
SRs of animal studies are (1) the Collaborative Approach to
Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES; www.camarades.info) group
and (2) the SYstematic Review Centre for Laboratory animal
Experimentation (SYRCLE; www.SYRCLE.nl). CAMARADES is routinely performing systematic reviews of preclinical animal models of disease and has formed a worldwide
network. SYRCLE has focused on the development of
methodology and guidelines and offers teaching and training
internationally, in addition to performing collaborative
systematic reviews (Ritskes-Hoitinga et al. 2014).
In 2011, the Montréal Declaration on the synthesis of
evidence to advance the 3Rs principles in science was initiated to make people aware of the need for a change in animal
research. It was adopted by the participants of the 8th World
Conference on Alternatives and Animal Use in the Life
Sciences (Leenaars et al. 2012b). This Declaration is calling
for a change in the culture of planning, executing, reporting,
reviewing, and translating animal research via the promotion
and coordination of synthesis of evidence, including systematic review of animal studies.
The number of SRs performed is increasing (Korevaar
et al. 2011; van Luijk et al. 2014), and many examples
Volume 55, Number 3, doi: 10.1093/ilar/ilu043
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demonstrate its value. However, most animal researchers
presently receive no or only limited training in SR methodology and are unaware of its availability and potential. To
achieve more general awareness of the availability of the
methodology and its added value, and to have high-quality
SRs performed on a large scale, education and training in
SR methodology are needed. The Dutch parliament recently
accepted a motion stating that education and training in systematic reviews of animal studies should be part of the course
on laboratory animal science for animal researchers (comparable with Federation of European Laboratory Animal Science Associations [FELASA] category C or EU2010/63:
article 23.2.b functionary) in The Netherlands. In the context
of continuing professional development, SYRCLE is currently providing education and training to researchers in The
Netherlands funded by The Netherlands Organisation for
Health Research and Development (ZonMw). Introduction
of the SR methodology into the curriculum of BSc and
MSc students in relevant ﬁelds such as biology and biomedical sciences is ongoing and can be a great opportunity to introduce the next generation of researchers to the concept.
In order to facilitate the conduct of SRs of animal studies, a
number of useful tools have been developed, such as the
step-by-step guide to ﬁnd all animal studies (Leenaars et al.
2012a); search ﬁlters (de Vries et al. 2011; 2014; Hooijmans
et al. 2010); a risk-of-bias tool (Hooijmans et al. 2014); a
practical guide to meta-analysis (Vesterinen et al. 2014);
and suggested guidance for the conduct, reporting, and critical appraisal of SRs (Sena et al. 2014). Nevertheless, there is a
need for further development of methodology tailored to the
conduct of high-quality SRs in preclinical animal studies. In
this respect, much can be learned from the Cochrane Collaboration, an international organization of more than 30,000
scientists, which has been collaborating on methodology,
guidelines, education, and conduct of SRs of clinical trials
for more than 20 years. The ﬁrst steps toward establishing a
Preclinical Animal Study Methods Group, in close cooperation with the Cochrane Collaboration, are currently being
taken (Ritskes-Hoitinga et al. 2014).
Through these activities, SRs will become common practice in the ﬁeld of animal studies and thereby help improve the
design of future animal and human studies. So far, SRs have
made a major contribution to the growing body of evidence
that improper conduct of animal studies generates unreliable
data and is unlikely to lead to clinical beneﬁt. By demonstrating the consequences of poor experimental design, SRs have
initiated the ﬁrst steps in a culture shift toward an improved
standard of practice in the ﬁeld of animal experimentation.
During this process, SRs act and have acted in synergy with
other initiatives, such as reporting guidelines (e.g., Animal
Research: Reporting of in Vivo Experiments [ARRIVE]
guidelines, Gold Standard Publication Checklist, and ILAR
Guidance) and education on experimental design (e.g.,
FRAME’s training schools). As awareness continues to
grow (through publication of SRs, international meetings,
and education), researchers, journals, ethics committees,
and funding bodies will be motivated to strive for better
435

Downloaded from http://ilarjournal.oxfordjournals.org/ at Katholieke Universiteit on December 30, 2014

only clinically effective treatment for ischemic stroke). However, this technique has the potential for novel interventions to
ascertain where sufﬁcient data exist for evidence of a stable
treatment effect so that further animal studies are not required
to demonstrate efﬁcacy.
An example of the contribution SRs can make to reﬁnement
is provided by an SR of the cisplatin-induced ferret model of
emesis (Percie du Sert et al. 2011). Their meta-analysis on the
effects of ondansetron provided evidence that the observation
period in studies of anti-emetics could be reduced from 24
hours to 4 hours. Similarly, an SR by Percie du Sert and
colleagues (2012) suggested that reﬁnement could be attained
by using rats instead of nonhuman primates in selfadministration studies to determine the reinforcing properties
of opioid drugs. Currie and colleagues are currently conducting an SR of animal models of neuropathic pain (see www.
camarades.info for their SR protocol). One of the objectives
of this SR is to establish whether reﬁnements are possible
by using tests with a lower burden of pain/distress, avoiding
multiple tests, and shortening the duration of the tests.

preclinical science. This in turn encourages the use and enforcement of reporting guidelines and other initiatives concerning optimal registration, conduct and reporting of
animal studies. Such measures will directly improve the design of experiments, but also facilitate the conduct of more
high-quality SRs (which, for instance, can assess the actual
risk of bias in the included studies or draw more reliable conclusions regarding the inﬂuence of study characteristics such
as the sex of animals). Through awareness, evidence, and education, the much-needed new global standard of practice for
animal experiments will hopefully be achieved in the near
future. This new standard will ensure that the laboratory animals used are not wasted and their suffering is counterbalanced by maximal human beneﬁt.
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